Deal with GE boosts Fischer results
A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter
A $6.2 million windfall from the sale of its Tilt-C technology to GE Medical Systems helped Fischer Imaging of Denver land solidly in the black for its first quarter (end-April). The company also reported a 3.6% increase in product sales for the quarter on higher service revenue and increased mammography shipments.
Fischer posted revenues of $20.4 million, compared with sales of $13.7 million in the first quarter of 1998. Excluding the GE payment, Fischer would have posted sales of $14.2 million. Fischer in April agreed to sell manufacturing rights to Tilt-C to Milwaukee-based GE (SCAN 4/14/99).
On the profit side, Fischer recorded net income of $3.4 million, compared with a net loss of $1.1 million in the same period a year ago. The company posted an operating loss of $1.6 million for the quarter, due in large part to costs associated with the move of its manufacturing operations from Addison, IL, to Denver.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
